Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia.

Department of Surgery and Anesthesiology, Gaston Memorial Hospital, Gastonia, North Carolina, USA.
The Annals of thoracic surgery (Impact Factor: 3.45). 08/2005; 80(1):299-303. DOI: 10.1016/j.athoracsur.2004.08.037
Source: PubMed

ABSTRACT The use of heparin in patients with heparin-induced thrombocytopenia (HIT) may result in severe complications or death. The diagnosis of HIT is frequently uncertain, however. Alternative anticoagulants in at-risk patients undergoing cardiac surgery with cardiopulmonary bypass remain problematic. The novel short-acting, direct-thrombin inhibitor bivalirudin is the only alternative to heparin/protamine being used in elective non-HIT patients during CPB.
Four patients with severe thrombocytopenia after heparin exposure and suspected acute HIT underwent on-pump coronary artery bypass grafting surgery with preemptive use of bivalirudin. A continuous bivalirudin infusion was used during cardiopulmonary bypass, and activated clotting times were used to monitor anticoagulation.
Anticoagulation with bivalirudin during cardiopulmonary bypass was effective and uncomplicated. Duration of operation was not prolonged, and perioperative blood loss and transfusion rates were acceptable. Activated clotting times were helpful for monitoring anticoagulation in these patients.
These data provide further evidence of the feasibility of bivalirudin for anticoagulation during on-pump coronary artery bypass graft surgery in urgent clinical situations.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In recent years some new antithrombotics have been studied or in part licensed, which have proven to be highly effective and, therefore, may replace the well-known anticoagulants such as unfractionated heparin, low-molecular-weight heparin and warfarin in the future. The purpose of this review is to provide an introduction to the pharmacologic profile and clinical indications of the new direct thrombin inhibitors bivalirudin, argatroban, ximelagatran as well as the indirect factor Xa (FXa) inhibitors fondaparinux and idraparinux. In particular, this article focuses on implications for the safe use of these new agents in surgery and anesthesia, and discusses therapeutic options for drug-induced bleeding.
    Transfusion Alternatives in Transfusion Medicine 10/2006; 8(3):164 - 174.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antiphospholipid syndrome (APLS) is a rare syndrome mainly characterized by several hyper-coagulable complications and therefore, implicated in the operated cardiac surgery patient. APLS comprises clinical features such as arterial or venous thromboses, valve disease, coronary artery disease, intracardiac thrombus formation, pulmonary hypertension and dilated cardiomyopathy. The most commonly affected valve is the mitral, followed by the aortic and tricuspid valve. For APLS diagnosis essential is the detection of so-called antiphospholipid antibodies (aPL) as anticardiolipin antibodies (aCL) or lupus anticoagulant (LA). Minor alterations in the anticoagulation, infection, and surgical stress may trigger widespread thrombosis. The incidence of thrombosis is highest during the following perioperative periods: preoperatively during the withdrawal of warfarin, postoperatively during the period of hypercoagulability despite warfarin or heparin therapy, or postoperatively before adequate anticoagulation achievement. Cardiac valvular pathology includes irregular thickening of the valve leaflets due to deposition of immune complexes that may lead to vegetations and valve dysfunction; a significant risk factor for stroke. Patients with APLS are at increased risk for thrombosis and adequate anticoagulation is of vital importance during cardiopulmonary bypass (CPB). A successful outcome requires multidisciplinary management in order to prevent thrombotic or bleeding complications and to manage perioperative anticoagulation. More work and reporting on anticoagulation management and adjuvant therapy in patients with APLS during extracorporeal circulation are necessary.
    Journal of Cardiothoracic Surgery 11/2010; 5:101. · 0.90 Impact Factor
  • Indian journal of anaesthesia 01/2012; 56(1):98-9.